Testing skipping breast surgery or radiation for top responders
Part of Cancer, Skin clinical trials.
This trial studies whether some people with early-stage breast cancer who respond extremely well to hormone/chemo/targeted treatment can safely skip breast surgery and/or radiation. It aims to reduce side effects without increasing cancer risk in carefully selected patients.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have early-stage, one-breast (unicentric) invasive breast cancer without spread to distant organs
- You must be able to plan breast-conserving treatment (lumpectomy instead of mastectomy)
- Your cancer subtype must match one of the trial’s groups (HER2-positive, or triple-negative, or ER/PR-positive/HER2-negative)
- Your lymph node ultrasound must not show many suspicious nodes (and any suspicious ones may need biopsy)
- If you’re triple-negative or HER2-positive, your age must meet the trial’s lower age limits; if ER/PR-positive/HER2-negative, there are also specific score/tumor-size rules
- You should not be pregnant and should not have prior radiation that would prevent required treatment
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether women with certain aggressive breast cancers (HER2-positive without hormone receptors, or triple-negative) can safely skip breast surgery if chemotherapy makes their tumor completely disappear. The goal is to avoid surgery and its side effects when it may no longer be needed.
This trial tests whether women who have a complete response to chemotherapy before breast-conserving surgery can safely skip a special radiation boost to the tumor bed. It aims to reduce unnecessary treatment side effects while maintaining good outcomes.
This trial tests whether women and men with advanced, non-metastatic breast cancer can safely skip an extra radiation boost to the lymph nodes if their tumors respond well to pre-surgery chemotherapy or targeted therapy. The goal is to reduce side effects while keeping cancer control.
This trial tests whether women with HER2-positive or triple-negative breast cancer who had a complete response to chemotherapy can safely skip radiation or additional surgery. If you had a complete tumor response after chemo and had breast-conserving surgery, you may be eligible.
This trial tests whether older women with very low-risk, hormone-positive breast cancer can safely skip endocrine therapy (hormone-blocking pills) and radiation after lumpectomy. It aims to maintain quality of life while keeping cancer from coming back.
This trial tests whether some women with low-risk breast cancer that has spread to a few lymph nodes can safely skip radiation therapy after surgery. It aims to reduce side effects while keeping the cancer from coming back.
Hear when a new HER2 Positive Breast Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.